Sudip Bandyopadhyay believes that investors will receive good returns and dividends from Mankind Pharma, praising the domestic pharma focused company's strong product portfolio, fantastic distribution and successful domestic empire. Advising that the company is a good purchase for long-term investors, Bandyopadhyay is confident that Mankind Pharma is a smart choice for investors looking for stable, smart management in a segment with a significant tailwind.